{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-009739","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.343367+00:00","generated_at":"2026-05-17T23:40:52.009193+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aclaris ATI-2138 Phase 2a AD trial meets primary and key secondary endpoints; 60.5% mean EASI improvement at week 12","bullets":["14 patients enrolled; 10 per protocol; no SAEs or discontinuations; well tolerated with mild, transient TRAEs.","Mean EASI improvement 60.5% (77.1% excluding one outlier); 62.5% achieved ≥4-point itch reduction at week 12.","PD data show near-complete ITK target occupancy and downregulation of Th2, Th1/Th17, and fibrosis markers.","Company plans to further develop ATI-2138 in alopecia areata and explore other indications.","Preclinical work ongoing for next-gen ITK inhibitors; new INDs expected starting 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-009739","json":"https://secwatch.observer/filing/0001558370-25-009739.json","markdown":"https://secwatch.observer/filing/0001558370-25-009739.md","text":"https://secwatch.observer/filing/0001558370-25-009739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837025009739/0001558370-25-009739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837025009739/acrs-20250729x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:40:52.009193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}